Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Fundamental Analysis

NASDAQ:GPCR - Nasdaq - US86366E1064 - ADR - Currency: USD

19.57  +0.56 (+2.95%)

After market: 19.57 0 (0%)

Fundamental Rating

3

Taking everything into account, GPCR scores 3 out of 10 in our fundamental rating. GPCR was compared to 193 industry peers in the Pharmaceuticals industry. GPCR has a great financial health rating, but its profitability evaluates not so good. GPCR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GPCR had negative earnings in the past year.
GPCR had a negative operating cash flow in the past year.
In the past 5 years GPCR always reported negative net income.
GPCR had a negative operating cash flow in each of the past 5 years.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

GPCR has a better Return On Assets (-16.54%) than 63.21% of its industry peers.
GPCR has a Return On Equity of -17.38%. This is in the better half of the industry: GPCR outperforms 72.54% of its industry peers.
Industry RankSector Rank
ROA -16.54%
ROE -17.38%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GPCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

GPCR has more shares outstanding than it did 1 year ago.
There is no outstanding debt for GPCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 15.48 indicates that GPCR is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 15.48, GPCR belongs to the top of the industry, outperforming 89.12% of the companies in the same industry.
There is no outstanding debt for GPCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.48
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

GPCR has a Current Ratio of 23.29. This indicates that GPCR is financially healthy and has no problem in meeting its short term obligations.
GPCR has a Current ratio of 23.29. This is amongst the best in the industry. GPCR outperforms 92.75% of its industry peers.
GPCR has a Quick Ratio of 23.29. This indicates that GPCR is financially healthy and has no problem in meeting its short term obligations.
GPCR's Quick ratio of 23.29 is amongst the best of the industry. GPCR outperforms 92.75% of its industry peers.
Industry RankSector Rank
Current Ratio 23.29
Quick Ratio 23.29
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GPCR have decreased strongly by -10.14% in the last year.
EPS 1Y (TTM)-10.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-326.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.44% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.31%
EPS Next 2Y4.32%
EPS Next 3Y1.5%
EPS Next 5Y14.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GPCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GPCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.32%
EPS Next 3Y1.5%

More info and screens

0

5. Dividend

5.1 Amount

GPCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (7/14/2025, 6:07:54 PM)

After market: 19.57 0 (0%)

19.57

+0.56 (+2.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners98.8%
Inst Owner Change0%
Ins Owners2.74%
Ins Owner Change29.35%
Market Cap1.13B
Analysts86.32
Price Target80.89 (313.34%)
Short Float %45.22%
Short Ratio8.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-224.6%
Min EPS beat(2)-246.94%
Max EPS beat(2)-202.27%
EPS beat(4)1
Avg EPS beat(4)-160.85%
Min EPS beat(4)-246.94%
Max EPS beat(4)22.26%
EPS beat(8)2
Avg EPS beat(8)-132.96%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.85%
PT rev (3m)-1.06%
EPS NQ rev (1m)-2.27%
EPS NQ rev (3m)-8.07%
EPS NY rev (1m)19.81%
EPS NY rev (3m)1.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-2.28
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-2.37
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS0
BVpS14.33
TBVpS14.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.54%
ROE -17.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 138.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.29
Quick Ratio 23.29
Altman-Z 15.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)306.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-326.32%
EPS Next Y35.31%
EPS Next 2Y4.32%
EPS Next 3Y1.5%
EPS Next 5Y14.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.72%
EBIT Next 3Y-29.79%
EBIT Next 5Y-4.45%
FCF growth 1Y-44.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.73%
OCF growth 3YN/A
OCF growth 5YN/A